Company Information


Press Releases   


Company Information


        Management Team

        IR Contacts


Stock Data     


Financial Filings    


Corporate Governance     

Annual Reports

Email Alerts


Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Our lead product, macimorelin, is the only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen™, through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. The Company owns all rights to macimorelin outside of the U.S. and Canada.


Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.


The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets with the goal of monetizing their value. 

©2020 Aeterna Zentaris  All rights reserved.
  • Twitter
  • LinkedIn
  • Facebook